MedTrace Logo

PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdel

NCT03199950 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1366

Last updated 2017-06-27

No results posted yet for this study

Summary

The hospital pharmacy at the Zuyderland Medical Centre developed the DElirium MOdel (DEMO) to predict which patients are at risk of developing a delirium in patients aged 60 or older. With this delirium risk prediction model we aim to predict more accurately which patients are at high risk of developing a delirium and want to investigate if these patients can benefit from prophylactic haloperidol.

Conditions

  • Delirium

Interventions

DRUG

Haloperidol

Haloperidol 2dd1mg (08.00am - 10.00pm)

DRUG

Placebo Oral Tablet

Placebo oral 2dd (08.00am - 10.00pm)

Sponsors & Collaborators

  • Zuyderland Medisch Centrum

    lead OTHER

Principal Investigators

  • Hugo van der Kuy · Zuyderland MC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-23
Primary Completion
2018-11-23
Completion
2018-11-23

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03199950 on ClinicalTrials.gov